Non-sedating antihistamines in the treatment of chronic idiopathic urticaria using patient-reported outcomes

References

• Greaves MW. Chronic urticaria. N Engl J Med 1995;332:1767–721. Greaves MW. Chronic urticaria. N Engl J Med 1995;332:1767–72
   PubMed Web of Science ®Google Scholar
• Kobza Black A, Greaves MW. Antihistamines in urticaria and angioedema. Clin Allergy Immunol 2002;17:249–862. Kobza Black A, Greaves MW. Antihistamines in urticaria and angioedema. Clin Allergy Immunol 2002;17:249–86
   PubMedGoogle Scholar
• Zuberbier T, Bindslev-Jensen C, Canonica W, et al. EAACI/GA2LEN/EDF guideline: definition, classification and diagnosis of urticaria. Allergy 2006;61:316–203. Zuberbier T, Bindslev-Jensen C, Canonica W, et al. EAACI/GA2LEN/EDF guideline: definition, classification and diagnosis of urticaria. Allergy 2006;61:316–20
   PubMed Web of Science ®Google Scholar
• Greaves MW. Chronic idiopathic urticaria. Curr Opin Allergy Clin Immunol 2003;3:363–84. Greaves MW. Chronic idiopathic urticaria. Curr Opin Allergy Clin Immunol 2003;3:363–8
   PubMedGoogle Scholar
• Gaig P, Olona M, Muñoz Lejarazu D, et al. Epidemiology of urticaria in Spain. J Invest Allergol Clin Immunol 2004;14:214–205. Gaig P, Olona M, Muñoz Lejarazu D, et al. Epidemiology of urticaria in Spain. J Invest Allergol Clin Immunol 2004;14:214–20
   PubMed Web of Science ®Google Scholar
• Greaves MW. Chronic urticaria. J Allergy Clin Immunol 2000;105:664–726. Greaves MW. Chronic urticaria. J Allergy Clin Immunol 2000;105:664–72
   PubMed Web of Science ®Google Scholar
• O'Donnell BF, Lawlor F, Simpson J, et al. The impact of chronic urticaria on quality of life. Br J Dermatol 1997;136:197–2017. O'Donnell BF, Lawlor F, Simpson J, et al. The impact of chronic urticaria on quality of life. Br J Dermatol 1997;136:197–201
   PubMed Web of Science ®Google Scholar
• Grob J-J, Revuz J, Ortonne J-P, et al. Comparative study of the impact of chronic urticaria, psoriasis and atopic dermatitis on the quality of life. Br J Dermatol 2005;152:289–958. Grob J-J, Revuz J, Ortonne J-P, et al. Comparative study of the impact of chronic urticaria, psoriasis and atopic dermatitis on the quality of life. Br J Dermatol 2005;152:289–95
   PubMed Web of Science ®Google Scholar
• Zuberbier T, Bindslev-Jensen C, Canonica W, et al. EAACI/GA2LEN/EDF guideline: management of urticaria. Allergy 2006;61:321–319. Zuberbier T, Bindslev-Jensen C, Canonica W, et al. EAACI/GA2LEN/EDF guideline: management of urticaria. Allergy 2006;61:321–31
   PubMed Web of Science ®Google Scholar
• Joint Task Force on Practice Parameters. Part II: chronic urticaria/angioedema. Ann Allergy Asthma Immunol 2000;85:532–4410. Joint Task Force on Practice Parameters. Part II: chronic urticaria/angioedema. Ann Allergy Asthma Immunol 2000;85:532–44
   Web of Science ®Google Scholar
• Ring J, Hein R, Gauger A, et al. and the Desloratadine Study Group. Once-daily desloratadine improves the signs and symptoms of chronic idiopathic urticaria: a randomized, double-blind, placebo-controlled study. Int J Dermatol 2001;40:72–611. Ring J, Hein R, Gauger A, et al. and the Desloratadine Study Group. Once-daily desloratadine improves the signs and symptoms of chronic idiopathic urticaria: a randomized, double-blind, placebo-controlled study. Int J Dermatol 2001;40:72–6
   PubMed Web of Science ®Google Scholar
• Monroe E, Finn A, Patel P, et al. and the Desloratadine Urticaria Study Group. Efficacy and safety of desloratadine 5 mg once daily in the treatment of chronic idiopathic urticaria: a double-blind, randomized, placebo-controlled trial. J Am Acad Dermatol 2003;48:535–4112. Monroe E, Finn A, Patel P, et al. and the Desloratadine Urticaria Study Group. Efficacy and safety of desloratadine 5 mg once daily in the treatment of chronic idiopathic urticaria: a double-blind, randomized, placebo-controlled trial. J Am Acad Dermatol 2003;48:535–41
   PubMed Web of Science ®Google Scholar
• Ortonne J-P, Grob J-J, Auquier P, et al. Efficacy and safety of desloratadine in adults with chronic idiopathic urticaria: a randomized, double-blind, placebo-controlled, multicenter trial. Am J Clin Dermatol 2007;8:37–4213. Ortonne J-P, Grob J-J, Auquier P, et al. Efficacy and safety of desloratadine in adults with chronic idiopathic urticaria: a randomized, double-blind, placebo-controlled, multicenter trial. Am J Clin Dermatol 2007;8:37–42
   PubMed Web of Science ®Google Scholar
• Thompson AK, Finn AF, Schoenwetter WF. Effect of 60 mg twice-daily fexofenadine HCl on quality of life, work and classroom productivity, and regular activity in patients with chronic idiopathic urticaria. J Am Acad Dermatol 2000;43:24–3014. Thompson AK, Finn AF, Schoenwetter WF. Effect of 60 mg twice-daily fexofenadine HCl on quality of life, work and classroom productivity, and regular activity in patients with chronic idiopathic urticaria. J Am Acad Dermatol 2000;43:24–30
   PubMed Web of Science ®Google Scholar
• Spector SL, Shikiar R, Harding G, et al. The effect of fexofenadine hydrochloride on productivity and quality of life in patients with chronic idiopathic urticaria. Cutis 2007;79:157–6215. Spector SL, Shikiar R, Harding G, et al. The effect of fexofenadine hydrochloride on productivity and quality of life in patients with chronic idiopathic urticaria. Cutis 2007;79:157–62
   PubMed Web of Science ®Google Scholar
• Kapp A, Pichler WJ. Levocetirizine is an effective treatment in patients with chronic idiopathic urticaria: a randomized, double-blind, placebo-controlled, parallel, multicenter study. Int J Dermatol 2006;45:469–7416. Kapp A, Pichler WJ. Levocetirizine is an effective treatment in patients with chronic idiopathic urticaria: a randomized, double-blind, placebo-controlled, parallel, multicenter study. Int J Dermatol 2006;45:469–74
   PubMed Web of Science ®Google Scholar
• Monroe E. Review of H1 antihistamines in the treatment of chronic idiopathic urticaria. Cutis 2005;76:118–2617. Monroe E. Review of H1 antihistamines in the treatment of chronic idiopathic urticaria. Cutis 2005;76:118–26
   PubMed Web of Science ®Google Scholar
• Zulal E. The leukotriene receptor antagonist montelukast in the treatment of chronic idiopathic urticaria: a single blind, placebo-controlled, crossover clinical study. J Allergy Clin Immunol 2002;110:484–818. Zulal E. The leukotriene receptor antagonist montelukast in the treatment of chronic idiopathic urticaria: a single blind, placebo-controlled, crossover clinical study. J Allergy Clin Immunol 2002;110:484–8
   PubMed Web of Science ®Google Scholar
• Bagentose SE, Levin L, Bernstein JA. The addition of zafirlukast to cetirizine improves the treatment of chronic urticaria in patients with positive autologous serum skin test results. J Allergy Clin Immunol 2004;113:134–4019. Bagentose SE, Levin L, Bernstein JA. The addition of zafirlukast to cetirizine improves the treatment of chronic urticaria in patients with positive autologous serum skin test results. J Allergy Clin Immunol 2004;113:134–40
   PubMed Web of Science ®Google Scholar
• Kozel MMA, Sabroe RA. Chronic urticaria: aetiology, management and current and future treatment options. Drugs 2004;64:2515–3620. Kozel MMA, Sabroe RA. Chronic urticaria: aetiology, management and current and future treatment options. Drugs 2004;64:2515–36
   PubMed Web of Science ®Google Scholar
• Strachan D. Urticaria, chronic. Available from http://www.emedicine.com/derm/topic443.htm#section∼medication [Last accessed 18 Jan 2008]21. Strachan D. Urticaria, chronic. Available from http://www.emedicine.com/derm/topic443.htm#section∼medication [Last accessed 18 Jan 2008]
   Google Scholar
• Nesbitt LT. Glucorticoids. In: Bolonga JL, Jorizzo JL, Rapini RP, editors. Dermatology. London: Mosby, 2003, pp. 1979–8922. Nesbitt LT. Glucorticoids. In: Bolonga JL, Jorizzo JL, Rapini RP, editors. Dermatology. London: Mosby, 2003, pp. 1979–89
   Google Scholar
• Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI) – a simple practical measure for routine clinical use. Clin Exp Dermatol 1994;19:210–623. Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI) – a simple practical measure for routine clinical use. Clin Exp Dermatol 1994;19:210–6
   PubMed Web of Science ®Google Scholar
• Kaplan AP, Spector SL, Meeves S, et al. Once-daily fexofenadine treatment for chronic idiopathic urticaria: a multicenter, randomized, double-blind, placebo-controlled study. Ann Allergy Asthma Immunol 2005;94:662–924. Kaplan AP, Spector SL, Meeves S, et al. Once-daily fexofenadine treatment for chronic idiopathic urticaria: a multicenter, randomized, double-blind, placebo-controlled study. Ann Allergy Asthma Immunol 2005;94:662–9
   PubMed Web of Science ®Google Scholar
• Breneman DL. Cetirizine versus hydroxyzine and placebo in chronic idiopathic urticaria. Ann Pharmacother 1996;30:1075–925. Breneman DL. Cetirizine versus hydroxyzine and placebo in chronic idiopathic urticaria. Ann Pharmacother 1996;30:1075–9
   PubMed Web of Science ®Google Scholar
• Tiplica G-S, Salavastru CM, Popescu S. Desloratadine improves symptoms and reduces interference with sleep and daily activities in patients with chronic idiopathic urticaria. Presented at the XXV Congress of the European Academy of Allergology and Clinical Immunology, Vienna, Austria, 10–14 June 200626. Tiplica G-S, Salavastru CM, Popescu S. Desloratadine improves symptoms and reduces interference with sleep and daily activities in patients with chronic idiopathic urticaria. Presented at the XXV Congress of the European Academy of Allergology and Clinical Immunology, Vienna, Austria, 10–14 June 2006
   Google Scholar
• Grob J-J, Auquier P, Dreyfus I, et al. Quality of life in adults with chronic idiopathic urticaria receiving desloratadine: a randomized, double-blind, placebo-controlled study. J Eur Acad Dermatol Venereol 2008;22:87–9327. Grob J-J, Auquier P, Dreyfus I, et al. Quality of life in adults with chronic idiopathic urticaria receiving desloratadine: a randomized, double-blind, placebo-controlled study. J Eur Acad Dermatol Venereol 2008;22:87–93
   PubMed Web of Science ®Google Scholar
• Grob J-J, Auquier P, Ortonne J-P, et al. How to prescribe antihistamines for chronic idiopathic urticaria: desloratadine daily vs PRN and quality of life. Allergy 2008 [in press]28. Grob J-J, Auquier P, Ortonne J-P, et al. How to prescribe antihistamines for chronic idiopathic urticaria: desloratadine daily vs PRN and quality of life. Allergy 2008 [in press]
   PubMed Web of Science ®Google Scholar
• Seidenari S, Cirillo A, Amoroso S, et al. and the Italian Study Group on Desloratadine (DL) in Chronic Urticaria. Desloratadine 5 mg once daily improves quality of life in chronic idiopathic urticaria. G Ital Dermatol Venereol 2006;141:207–1429. Seidenari S, Cirillo A, Amoroso S, et al. and the Italian Study Group on Desloratadine (DL) in Chronic Urticaria. Desloratadine 5 mg once daily improves quality of life in chronic idiopathic urticaria. G Ital Dermatol Venereol 2006;141:207–14
   Google Scholar
• Nettis E, Colanardi MC, Paradiso MT, et al. Desloratadine in combination with montelukast in the treatment of chronic urticaria: a randomized, double-blind, placebo-controlled study. Clin Exp Allergy 2004;34:1401–730. Nettis E, Colanardi MC, Paradiso MT, et al. Desloratadine in combination with montelukast in the treatment of chronic urticaria: a randomized, double-blind, placebo-controlled study. Clin Exp Allergy 2004;34:1401–7
   PubMed Web of Science ®Google Scholar
• Lachapelle JM, Decroix J, Henrijean A, et al. Desloratadine 5 mg once daily improves the quality of life of patients with chronic idiopathic urticaria. J Eur Acad Dermatol Venereol 2006;20:288–9231. Lachapelle JM, Decroix J, Henrijean A, et al. Desloratadine 5 mg once daily improves the quality of life of patients with chronic idiopathic urticaria. J Eur Acad Dermatol Venereol 2006;20:288–92
   PubMed Web of Science ®Google Scholar
• Kim H, Lynde C. Desloratadine improves signs/symptoms and QOL in CIU: the Canadian experience. Archives Drug Information 2008 [in press]32. Kim H, Lynde C. Desloratadine improves signs/symptoms and QOL in CIU: the Canadian experience. Archives Drug Information 2008 [in press]
   PubMedGoogle Scholar
• Geha RS, Meltzer EO. Desloratadine: a new, nonsedating, oral antihistamine. J Allergy Clin Immunol 2001;107:751–6233. Geha RS, Meltzer EO. Desloratadine: a new, nonsedating, oral antihistamine. J Allergy Clin Immunol 2001;107:751–62
   PubMed Web of Science ®Google Scholar
• Murdoch D, Goa KL, Keam SJ. Desloratadine: an update of its efficacy in the management of allergic disorders. Drugs 2003;63:2051–7734. Murdoch D, Goa KL, Keam SJ. Desloratadine: an update of its efficacy in the management of allergic disorders. Drugs 2003;63:2051–77
   PubMed Web of Science ®Google Scholar
• Berger WE. The safety and efficacy of desloratadine for the management of allergic disease. Drug Saf 2005;28:1101–1835. Berger WE. The safety and efficacy of desloratadine for the management of allergic disease. Drug Saf 2005;28:1101–18
   PubMed Web of Science ®Google Scholar
• Aerius summary of product characteristics. Available from http://www.emea.europa.eu/humandocs/PDFs/EPAR/aerius/H-313-PI-en-pdf [Last accessed 18 Jan 2008]36. Aerius summary of product characteristics. Available from http://www.emea.europa.eu/humandocs/PDFs/EPAR/aerius/H-313-PI-en-pdf [Last accessed 18 Jan 2008]
   Google Scholar
• Rikken G, Scharf MB, Danzig MR, et al. Desloratadine and alcohol co-administration: no increase in impairment of performance over that induced by alcohol alone. Allergy 2000;55 Suppl 63:277 [abstract 993]37. Rikken G, Scharf MB, Danzig MR, et al. Desloratadine and alcohol co-administration: no increase in impairment of performance over that induced by alcohol alone. Allergy 2000;55 Suppl 63:277 [abstract 993]
   Google Scholar
• Nicholson AN, Handford ADF, Turner C, et al. Studies on performance and sleepiness with the H1-antihistamine, desloratadine. Aviat Space Environ Med 2003;74:809–1538. Nicholson AN, Handford ADF, Turner C, et al. Studies on performance and sleepiness with the H1-antihistamine, desloratadine. Aviat Space Environ Med 2003;74:809–15
   PubMed Web of Science ®Google Scholar
• Borchard UHJ, Daly AF, Plenker A. Desloratadine: safety and tolerability data in clinical practice. J Allergy Clin Immunol 2003;111 part 2:S74 [abstract 17]39. Borchard UHJ, Daly AF, Plenker A. Desloratadine: safety and tolerability data in clinical practice. J Allergy Clin Immunol 2003;111 part 2:S74 [abstract 17]
   Google Scholar
• Rodrigo FG, Vieira AP. and the Desloratadine in Chronic Idiopathic Urticaria Study Group. Desloratadine improves pruritus in patients with chronic idiopathic urticaria. Presented at the XXVI Congress of the European Academy of Allergology and Clinical Immunology, Göteborg, Sweden, 9–13 June 200740. Rodrigo FG, Vieira AP. and the Desloratadine in Chronic Idiopathic Urticaria Study Group. Desloratadine improves pruritus in patients with chronic idiopathic urticaria. Presented at the XXVI Congress of the European Academy of Allergology and Clinical Immunology, Göteborg, Sweden, 9–13 June 2007
   Google Scholar